# One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease

Study · id `cardio:ct-nct04148820` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04148820](<https://clinicaltrials.gov/study/NCT04148820>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04148820

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04148820. Randomized; no masking; primary purpose treatment. Start 2019-11-01 (anticipated); primary completion 2021-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04148820, source copy `cardio:ctgov-nct04148820-2019-11-05`, retrieved 2026-10-26)
- Planned start: 2019-11-01 (anticipated) (ClinicalTrials.gov record NCT04148820, source copy `cardio:ctgov-nct04148820-2019-11-05`, retrieved 2026-10-26)
- Primary completion: 2021-10-31 (anticipated) (ClinicalTrials.gov record NCT04148820, source copy `cardio:ctgov-nct04148820-2019-11-05`, retrieved 2026-10-26)
- Completion: 2021-10-31 (anticipated) (ClinicalTrials.gov record NCT04148820, source copy `cardio:ctgov-nct04148820-2019-11-05`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT04148820, source copy `cardio:ctgov-nct04148820-2019-11-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04148820-2019-11-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease
- Acronym: ONCE
- Condition: Ischemic Heart Disease
- Intervention (Drug): Aspirin, Atorvastatin, Perindopril
- Lead sponsor: University of Roma La Sapienza
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: University of Roma La Sapienza (`cardio:org-university-of-roma-la-sapienza`)

## Provenance

Content hash: a52a9ef97321e74e9e4e4747673d737835f7167f6d1cf5de4be4669475e262c6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
